A Phase 1 Study to Determine the Pharmacokinetics and Pharmacodynamics of Single and Multiple Inhaled Doses of GH001 in Healthy Volunteers
Latest Information Update: 31 Mar 2022
At a glance
- Drugs 5 Methoxy N N Dimethyltryptamine (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors GH Research
Most Recent Events
- 28 Mar 2022 According to the GH Research media release, the full results of the trial support that an interval down to 1 hour between individual doses of the IDR is feasible for use in future clinical trials.
- 13 Dec 2021 Status changed from planning to completed.
- 03 Dec 2020 New trial record